If rollout does not speed up, the knock-on effect will have widespread global repercussions
Covid vaccine is not a shot in the arm for all investors
‘There are certain sectors where the long-term viability is in question’
Covid vaccine won’t result in a biotech payday
Virus mutations and public scrutiny will make it tough for firms to cash in on a cure
Multi-asset boutique increases European exposure
Boutique London-based asset manager Kestrel Investment Partners is increasing exposure to Europe’s financial, telecom and pharmaceutical sectors on the back of the European Central Bank’s quantitative easing (QE) decision.
Biotech and pharma: a remedy for turbulent times?
In the decade since the financial crisis, pharmaceuticals, healthcare and bioscience-focused funds have significantly outperformed the MSCI World index.